PA
SRPT icon

Procyon Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Procyon Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-2
Closed – – 938
2020
Q2 		$0 Sell
2
-250
-99% -$34K ﹤0.01% 1183
2020
Q1 		$25K Hold
252
– – 0.02% 441
2019
Q4 		$33K Buy
+252
New +$25.4K 0.02% 410

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Procyon Advisors's SRPT Position: Q3 2020 in Review

Procyon Advisors sold out of Sarepta Therapeutics (SRPT) in Q3 2020, closing a stake of 2 shares.

Procyon Advisors first reported a position in SRPT in Q4 2019 and held it in 3 quarters. The position peaked at $33K in Q4 2019. 403 funds tracked by Wall St. Rank hold SRPT as of Q3 2020.

  • Procyon Advisors reported no remaining Sarepta Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Procyon Advisors sold 2 Sarepta Therapeutics shares in Q3 2020.
  • Procyon Advisors first reported a position in Sarepta Therapeutics in Q4 2019 and held it in 3 quarters.
  • Procyon Advisors's Sarepta Therapeutics position peaked at $33K in Q4 2019.
  • 403 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2020.

Based on Procyon Advisors's 13F filing for Q3 2020, filed 22 Oct 2020.